D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.

CXCR4 D-peptide-based probe PET imaging cancer

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
05 Oct 2021
Historique:
received: 13 08 2021
revised: 16 09 2021
accepted: 29 09 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

Positron emission tomography (PET) imaging of the C-X-C chemokine receptor 4 (CXCR4) with [

Identifiants

pubmed: 34683912
pii: pharmaceutics13101619
doi: 10.3390/pharmaceutics13101619
pmc: PMC8537445
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Stichting Tegen Kanker
ID : C/2020/1528
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 12R3119N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : I001719N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : G0H1216N

Références

Biochem Biophys Res Commun. 2013 Jun 14;435(4):646-50
pubmed: 23688427
Theranostics. 2017 Jun 11;7(9):2350-2362
pubmed: 28744319
Biochemistry. 2000 Apr 4;39(13):3782-7
pubmed: 10736178
Stem Cells Dev. 2012 Aug 10;21(12):2142-51
pubmed: 22121892
Theranostics. 2015 Mar 01;5(6):618-30
pubmed: 25825601
J Nucl Med. 2005 Oct;46(10):1696-700
pubmed: 16204720
J Pharm Biomed Anal. 2015;111:209-14
pubmed: 25898315
Tomography. 2016 Jun;2(2):85-93
pubmed: 30042959
J Med Chem. 2017 Jun 22;60(12):4735-4779
pubmed: 28165741
J Vis Exp. 2018 Mar 10;(133):
pubmed: 29578516
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
Sci Rep. 2019 Oct 25;9(1):15284
pubmed: 31653903
J Mol Med (Berl). 2014 May;92(5):433-9
pubmed: 24722947
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
EJNMMI Radiopharm Chem. 2020 Nov 12;5(1):25
pubmed: 33180205
Nat Protoc. 2012 May 17;7(6):1138-44
pubmed: 22596226
EJNMMI Res. 2013 May 08;3(1):36
pubmed: 23651690
J Nucl Med. 2017 Sep;58(Suppl 2):77S-82S
pubmed: 28864616
J Nucl Med. 2017 Sep;58(9):1435-1441
pubmed: 28450554
J Nucl Med. 2016 Feb;57(2):248-51
pubmed: 26564323
J Nucl Med. 2020 Jan;61(1):123-128
pubmed: 31201250
J Biol Chem. 2002 May 17;277(20):17476-85
pubmed: 11880384
EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4
pubmed: 31997090
Ann Nucl Med. 2018 Oct;32(8):503-511
pubmed: 30105558
Biochemistry. 2014 Aug 5;53(30):4881-3
pubmed: 25058910
Theranostics. 2017 Jul 14;7(11):2924-2939
pubmed: 28824726
Theranostics. 2020 Jul 9;10(18):8264-8280
pubmed: 32724470
Br J Pharmacol. 2020 Aug;177(16):3617-3624
pubmed: 32662519

Auteurs

Kaat Luyten (K)

Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.

Tom Van Loy (T)

Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Christopher Cawthorne (C)

Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium.

Christophe M Deroose (CM)

Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium.

Dominique Schols (D)

Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Guy Bormans (G)

Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.

Frederik Cleeren (F)

Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.

Classifications MeSH